Walsh Medical Media
Walsh Medical Media is a medical publishing brand associated with OMICS Publishing Group.
Last updated August 25, 2026
AI crawler reads
No AI crawler has read this profile since Oct 28, 2026.
Overview
Walsh Medical Media is a medical publishing brand identified in reference material as one of the subsidiaries or brands associated with OMICS Publishing Group. Publicly available information about Walsh Medical Media as a distinct operating entity is limited, and the available material does not establish a separate founding date, founder, headquarters, ownership structure, executive team, financial profile, or current operating status for the brand. The brand appears in the context of OMICS's broad open-access publishing portfolio. OMICS was founded in 2007 by Srinubabu Gedela and began publishing its first journal in 2008. By the mid-2010s, OMICS claimed hundreds of journal titles and operated a substantial conference business alongside journal publishing. The group used a gold open-access model in which authors generally paid publication charges while published articles were made freely available. Its wider portfolio included medical, life-science, biotechnology, engineering, and other scientific titles, as well as conference and events brands. Walsh Medical Media should therefore be understood primarily as an associated medical-publishing label rather than as a separately documented global publisher. The available references do not identify particular Walsh Medical Media journals, book lines, conferences, editorial leaders, or product launches with sufficient confidence to describe them individually. The brand's own website is the principal identified web presence, but the supplied reference material does not provide enough verified information to characterize its current catalog or commercial activity. The reputation of the broader OMICS group is important context for the brand. OMICS was criticized by researchers, librarians, and academic commentators over alleged weaknesses in peer review, unclear or unexpected fees, misleading marketing, claims concerning indexing and impact metrics, and the use of academics' names in editorial or conference materials without adequate authorization. U.S. government action followed. In 2013, the U.S. Department of Health and Human Services sent a cease-and-desist letter concerning alleged misuse of the names and images of government personnel and institutions. In 2016, the U.S. Federal Trade Commission sued OMICS and related parties over alleged deceptive publishing and conference practices. A federal court entered a preliminary injunction in 2017, and in 2019 granted summary judgment for the FTC and ordered more than $50 million in monetary relief; the Ninth Circuit upheld that judgment in 2020. Those proceedings concerned OMICS Publishing Group and related companies rather than establishing separate findings against Walsh Medical Media specifically. Accordingly, the brand's historical and present status should not be overstated. It is best catalogued as an OMICS-associated medical publishing brand whose independent corporate identity, catalog, management, and current activity require further verification.
History
The documented history of Walsh Medical Media is sparse when separated from that of OMICS Publishing Group. Reference material identifies it as one of OMICS's subsidiaries or brands, but does not provide a reliable standalone founding year, founder, headquarters, incorporation record, executive roster, journal list, or operating-market profile. OMICS Publishing Group was established in 2007 by Srinubabu Gedela and launched its first open-access journal in 2008. The group expanded rapidly across scientific and medical publishing, claiming more than 200 journal titles by 2012 and more than 700 by 2015, although reference material states that many titles had little or no continuing content and that a substantial portion were defunct. The group also organized scientific conferences and events, which became a significant part of its business. Walsh Medical Media was listed among the medical and scientific brands used within this broader portfolio. The group's publishing model generally followed gold open access: authors or their institutions paid publication charges and readers could access published content without a subscription. Critics questioned the transparency of those charges, the handling of manuscript withdrawals, the rigor of peer review, the accuracy of indexing and impact-factor claims, and the use of researchers' names in editorial and conference promotion. These criticisms were directed principally at OMICS and its associated operations; the supplied material does not document a separate adjudicated finding specifically naming Walsh Medical Media. Several developments affected the standing of the wider group. In 2013, the U.S. Department of Health and Human Services sent OMICS a cease-and-desist letter over alleged misleading use of the names, images, or affiliations of U.S. government personnel and institutions. In 2014, PubMed Central reportedly blacklisted OMICS journals because of concerns about publishing practices, and in 2017 Scopus delisted several OMICS journals for publication-related concerns. OMICS also faced criticism over conferences that allegedly accepted poor-quality or nonsensical submissions and promoted academics as speakers without their authorization. In August 2016, the FTC filed its first lawsuit against an academic publisher, naming OMICS, affiliated entities, and Gedela. The case alleged that the defendants misrepresented peer review, editorial-board participation, indexing, journal metrics, and article-processing charges, and that they restricted manuscript withdrawals. A preliminary injunction was issued in 2017. In March 2019, the district court granted the FTC summary judgment and ordered more than $50 million in monetary relief and operational changes. The Ninth Circuit affirmed the result in September 2020. Because Walsh Medical Media is documented mainly through its association with OMICS, a complete independent chronology cannot be established from the available sources. Its catalog, current status, and relationship to OMICS after the legal proceedings remain unclear.
- 2020
Appeal judgment upheld
[1]The Ninth Circuit upheld the district court's judgment and monetary award against OMICS and related parties.
- 2019
Summary judgment entered against OMICS
[1]A U.S. district court granted the FTC summary judgment and ordered monetary relief exceeding $50 million, along with changes to OMICS publishing methods.
- 2016
FTC brings lawsuit against OMICS
[1]The Federal Trade Commission sued OMICS and related defendants over alleged deceptive academic-publishing and conference practices.
- 2014
PubMed Central blacklists OMICS journals
[1]PubMed Central reportedly removed or blacklisted OMICS journals amid concerns about their publishing practices.
- 2008
OMICS begins journal publishing
[1]OMICS launched its first open-access journal, beginning the expansion of the publishing portfolio that later included Walsh Medical Media.
- 2007
OMICS Publishing Group founded
[1]OMICS Publishing Group was founded by Srinubabu Gedela, establishing the corporate group with which Walsh Medical Media is associated.
Products and positioning
Medical and health-science publishing within the broader OMICS open-access journal portfolio.
Academic journals
Medical and health-science journals
Walsh Medical Media is identified as a medical publishing brand within the OMICS portfolio. The supplied references do not specify individual journal titles or establish which titles were operated under the Walsh Medical Media name. The brand is therefore best described at portfolio level as a label for medical and health-science scholarly publishing rather than through a verified list of flagship journals.
Controversies
2019
Federal court judgment against OMICS
The court found deceptive practices by OMICS and related defendants and ordered more than $50 million in monetary relief and changes to publishing practices. The Ninth Circuit affirmed the result in 2020.
2016
FTC deceptive-publishing litigation involving OMICS
The FTC alleged that OMICS and related defendants misrepresented peer-review procedures, editorial participation, indexing, journal metrics, and publication charges. The proceedings concerned the broader OMICS group; the available source does not state that Walsh Medical Media was separately adjudicated.
Brand decisions
2016
Expansion through a broad open-access publishing portfolioStrategyBackground
OMICS expanded across medical and scientific journals and associated conference activities, with Walsh Medical Media listed among its brands.
Action taken
The group used multiple publishing labels to develop a wide-ranging open-access academic portfolio.
Aftermath
The expansion increased the group's reach but also intensified scrutiny of editorial standards, fees, marketing, and indexing claims.
Sources2 sources
Cite this profile: Cite the canonical profile. /brand-wiki/walsh-medical-media · Editorial policy · How profiles are compiled